Millennium Management’s Neurocrine Biosciences NBIX Stock Holding History

Millennium Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,700	Closed	-$7.12M	–	6308
2025 Q3	$7.12M	Buy	+50,700	New	+$6.87M	﹤0.01%	2744
2025 Q1	–	Sell	-8,800	Closed	-$1.2M	–	6219
2024 Q4	$1.2M	Sell	8,800 -9,900	-53%	-$1.22M	﹤0.01%	4048
2024 Q3	$2.15M	Buy	+18,700	New	+$2.56M	﹤0.01%	3637
2023 Q4	–	Sell	-15,000	Closed	-$1.69M	–	6369
2023 Q3	$1.69M	Buy	+15,000	New	+$1.58M	﹤0.01%	3718
2017 Q1	–	Sell	-200,000	Closed	-$7.74M	–	3726
2016 Q4	$7.74M	Buy	+200,000	New	+$9.05M	0.02%	1067
2015 Q2	–	Sell	-100,000	Closed	-$3.97M	–	3655
2015 Q1	$3.97M	Hold	100,000	–	–	0.01%	1545
2014 Q4	$2.23M	Buy	+100,000	New	+$1.89M	﹤0.01%	1896

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's NBIX Position: Q1 2026 in Review

Millennium Management increased its Neurocrine Biosciences (NBIX) stake by 182% in Q1 2026, buying an estimated $107M and bringing the position to 1,247,447 shares worth $164M. The position accounts for 0.07% of the portfolio, ranked #263.

Millennium Management first reported a position in NBIX in Q2 2013 and has held it in 48 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Millennium Management held 1,247,447 shares of Neurocrine Biosciences worth $164M as of Q1 2026.
Millennium Management bought 804,581 Neurocrine Biosciences shares in Q1 2026, an estimated $107M.
Neurocrine Biosciences made up 0.07% of Millennium Management's portfolio in Q1 2026, its #263 holding.
Millennium Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 48 quarters since.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.